Cellicure provides innovative, cell-based immunotherapy technologies, customized treatment regimens and real world solutions to solve the current unmet therapeutic needs created by cancer, infectious diseases, and chronic inflammatory diseases.

OUR TECHNOLOGIES
Cellicure's proprietary systems deliver high-yield NK cell treatments with enhanced functionality and reduced toxicity compared to standard cytokine-based approaches.
Cellicure has developed patented CAR-NK technologies that have overcome the many challenges that arise from using NK cells and NK specific CARs for immunotherapy.
Cellicure’s CAR-T technology provides CAR-T cells with improved persistence abilities, rapidly accelerating immunotherapy efficiency.
Cellicure’s complete signaling CAR (csCAR-NK) enhances activation signaling and overcomes the inhibitory signaling barrier, resulting in complete activation of NK cells.
Cellicure’s NK expansion system (Effic-NKTM) simplifies the human NK expansion process, providing higher efficiency and lower cost.
Have questions about our cell-based immunotherapies? Reach out and our team will respond promptly.